Research & Publications
I am very pleased to be part of the Yale Fertility Center. I look forward to providing the best clinical experience for each of my patients while utilizing one of the most advanced reproductive facilities in the U.S. My approach is to provide the most compassionate and contemporary infertility services available to meet the individual needs and personal values of my patients. Areas of special clinical interest include optimizing age-related infertility, pre-implantation genetic diagnosis, male factor infertility, recurrent pregnancy loss, polycystic ovarian syndrome and fertility preservation. I am also the Program Director of the Yale REI Fellowship responsible for the mentoring, advanced training and organizing of post-graduate physicians who become board eligible in this sub-specialty after their 3 year experience at Yale.
My research includes the mechanisms of reproductive aging. This work has led to a simple blood test, antimullerian hormone (AMH), used worldwide today that helps determine the health of a woman’s ovaries, a rough estimate of her egg count and real time assessment of her biological clock. To learn more read: https://www.yalemedicine.org/stories/fertility-test/. or https://medicine.yale.edu/news/yale-medicine-magazine/overcoming-infertility/ or https://medicine.yale.edu/news/yale-medicine-magazine/a-grand-challenge-slowing-the-biological-clock/.
I am co-editing two books entitled "Optimizing the Management of Fertility in Women Over 40" to be published by Cambridge University Press scheduled for publication in Fall of 2022 and "Polycystic Ovary Syndrome - Current & Emerging Concepts: An Individualized Approach to Management" which was published by Springer in May of 2022.
Complete list of Published Work: https://www.ncbi.nlm.nih.gov/sites/myncbi/1B9unppU5pqg0L/bibliography/55102886/public/?sort=date&direction=descending
Li HJ, Seifer DB, Tal R. AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles. Reprod Biol Endocrinol 2023, 21: 19. PMID: 36739415, DOI: 10.1186/s12958-023-01066-w.
Correia KFB, Kraschel K, Seifer DB. State Insurance Mandates for in Vitro Fertilization are not Associated with Improving Racial and Ethnic Disparities in Utilization and Treatment Outcomes. Am J Obstet Gynecol. 2022 Nov 7;. doi: 10.1016/j.ajog.2022.10.043. [Epub ahead of print] PubMed PMID: 36356698.
Esencan E, Beroukhim G, Seifer DB. Age-related changes in Folliculogenesis and potential modifiers to improve fertility outcomes - A narrative review. Reprod Biol Endocrinol. 2022 Nov 17;20(1):156. doi: 10.1186/s12958-022-01033-x. Review. PubMed PMID: 36397149; PubMed Central PMCID: PMC9670479.
Curchoe CL, Tarafdar O, Aquilina MC, Seifer DB. SART CORS IVF registry: looking to the past to shape future perspectives. J Assist Reprod Genet. 2022 Oct 21;. doi: 10.1007/s10815-022-02634-6. [Epub ahead of print] PubMed PMID: 36269502.
Peipert BJ, Montoya MN, Bedrick BS, Seifer DB, Jain T. Impact of in vitro fertilization state mandates for third party insurance coverage in the United States: a review and critical assessment. Reprod Biol Endocrinol. 2022 Aug 4;20(1):111. doi: 10.1186/s12958-022-00984-5. Review. PubMed PMID: 35927756; PubMed Central PMCID: PMC9351254
Reprod Sci. 2022 Jul;29(7):2084-2088.
Fertil Steril. 2022 Feb;117(2):326-338.
Connecting the dots between oocyte quantity and quality in diminished ovarian reserve. Fertil Steril. 2021 Apr;115(4):890.
AMH Highly Correlates with Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve Independent of Age. J Clin Endocrinol Metab. 2021 Mar 17;. doi: 10.1210/clinem/dgab168. [Epub ahead of print]
Psychological experience and coping strategies of patients in the Northeast US delaying care for infertility during the COVID-19 pandemic. Reprod Biol Endocrinol. 2021 Feb 23;19(1):28.
Status of racial disparities between black and white women undergoing assisted reproductive technology in the US. Reprod Biol Endocrinol. 2020 Nov 19;18(1):113.
The association between anti-Müllerian hormone and vitamin 25(OH)D serum levels and polycystic ovarian syndrome in adolescent females. Reprod Biol Endocrinol. 2020 Nov 21;18(1):118.
Kotlyar A, Seifer DB. Anti-Mullerian hormone as a qualitative marker- or just quantity? Curr Opin Obstet Gynecol 32:219-226, 2020.
Seifer DB, Kallen AN. A counterintuitive lesson in family planning? Patience first: taking a gap year after live birth from assisted reproductive technology before frozen embryo transfer is performed. Fertil Steril 111:1109-1110, 2019.
Tal R, Seifer DB, Wantman E, Baker VL, Tal O. AMH as predictor of live birth following assisted reproductive technology: analysis of 85,062 fresh and thawed cycles from the SART COR database for 2012-2013. Fertil Steril. 109:258-265, 2018.
Kushnir VA, Seifer DB, Barad DH, Sen A, Gleicher N. Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. J Assist Reprod Genet. 2017 Sep;34(9):1105-1113.
Seifer DB, Tal O, Wantman E, Edul P, Baker VL. Prognostic indicators of ART outcomes of cycles with ultra-low serum antimüllerian hormone (AMH): a multivariate analysis of over 5000 autologous cycles from the SART CORS database for 2012-2013. Fertil Steril 105:385-93, 2016.
Seifer DB, Tal R (ed): Anti-Mullerian Hormone: Biology, Role in Ovarian Function and Clinical Significance. New York, Nova Science, 2016.
I also have had a research focus in population-based health outcomes research to gain better understanding of the trends of reproductive aging, health care disparities in IVF, vitamin D deficiency in reproductive health and a global improvement in the clinical practice of reproductive medicine. This has been achieved through collaborative studies and analysis of large clinical data sets from well characterized populations through the Assisted Reproductive Technologies Clinical Outcomes Reporting System (SART CORS), the Women's Interagency HIV Study (WIHS), the National Assisted Reproductive Technology Surveillance System (NASS) registries and the Reproductive Medicine Network (RMN).
Zagadailov P, Seifer DB, Shan H, Zarek SM, Hsu AL. Do state insurance mandates alter ICSI utilization? Reprod Biol Endocrinol. 2020 Apr 25;18(1):33. (NASS database)
Butts SF*, Seifer DB*, Koelper N, Senapati S, Sammel MD, Hoofnagle AN, Kelly A, Kraetz SA, Santoro N, Zhang H, Diamond MP, Legro RS. Vitamin D deficiency is associated with poor ovarian stimulation outcome in PCOS but not unexplained infertility. J Clin Endocrinol Metab, 2019 Feb 1;104(2):369-378. (RMN database) *co-first authors
Luke B, Brown MB, Wantman E, Seifer DB, Sparks AT, Lin PC, Doody KJ, Van Voorhis BJ, Spector LG. Risk of prematurity and infant morbidity and mortality by maternal fertility status and plurality.J Assist Reprod Genet. 2019 Jan;36(1):121-138. doi: 10.1007/s10815-018-1333-z. (SART CORS database linked with birth and death certificate database in 14 Departments of Health)
Luke B, Brown MB, Wantman E, Doody K, Seifer DB, Spector LG. Risk of severe maternal morbidity maternal age, fertility status, plurality and mode of delivery: A US study in eight states. Am J Obstet Gynecol. 2018 Oct 12. pii: S0002-9378(18)30894-9. doi: 10.1016/j.ajog.2018.10.012. (SART CORS database linked with birth certificate database in 8 Departments of Health)
Zagadailov P, Hsu A, Stern JE, Seifer DB. Temporal differences in utilization of intracytoplasmic sperm injection among U.S. regions. Obstet Gynecol. 2018 Aug;132(2):310-320. (NASS database)
Xu J, Lawson MS, Xu F, Du Y, Tkachenko OY, Bishop CV, Pejovic-Nezhat L, Seifer DB, Hennebold JD. Expression of vitamin D biosynthesis and signaling system in the rhesus macaque ovary: a role for regulating follicular development. Front Physiol 14;9:1600, 2018.
I am a past-president of the Society for Assisted Reproductive Technology (SART), the primary, national organization that sets clinical and laboratory guidelines as well as the standards for safety and quality metrics for the practice of IVF in the US. As such, I am interested in using patient-physician advocacy to move toward expanding insurance coverage for infertility treatment for those who are without such benefits as well as moving toward strategies of closing the gap in disparities of access and outcomes in the utilization of IVF. I am also actively encouraging and mentoring young Yale faculty to bring their energy and insight to a national level within SART.
Seifer DB, Wantman E, Sparks AE, Luke B, Doody KJ, Toner JP, van Voorhis BJ, Lin PC, Reindollar RH. National survey of the Society for Assisted Reproductive Technology membership regarding insurance coverage for assisted reproductive technologies. Fertil Steril. 2018 Nov;110(6):1081-1088.
As Co-Editor-in- Chief of Reproductive Biology and Endocrinology (RB&E) https://rbej.biomedcentral.com/ I am actively involved in encouraging the publication of quality and novel research in the reproductive sciences.
Education & Training
- MDUniversity of Illinois - Chicago, Medicine (1981)
Honors & Recognition
|America’s Top Doctors Castle Connolly Medical Guide for 20 years||Castle Connolly||2022|
|Ferring Innovation Grant for Racial Equality in Reproductive Medicine and Maternal Health (2021-22)||Ferring Pharmaceuticals||2021|
|Connecticut Top Docs||Connecticut Magazine||2021, 2022, 2023|
|Prize Paper Awards for SART and ASRM - Co-author||ASRM||2020|
|Prize Paper Award for Health Care Disparities- Co-author||ASRM||2019, 2022|
|Titus Fellowship Award||Yale School of Medicine||2019|
|ASRM Star Award||American Society of Reproductive Medicine||2016, 2017, 2018, 2019, 2020, 2021, 2022|
|Thomas Alva Edison Patent Award||Research and Development Council of New Jersey||2011|
|Inventor of the Year Award||New Jersey Inventors Hall of Fame||2011|
|Life Teacher Award||Maimonides Medical Center||2007|
|Society for Assisted Reproductive Technology (SART)||President of SART 2017-2018; Member of Presidential and Executive Council of Society for Assisted Reproductive Technology (SART) 2016 - 2021.||2017 - 2021|
|Reproductive Biology and Endocrinology||Co-Editor-in-Chief||2016 - Present|
|NICHD – NIH Reproduction, Andrology, Gynecology Study Section||2004 - 2008|
|FDA Advisory Committee Obstetrics and Gynecology Devices Panel||2001 - 2005|